Literature DB >> 15631257

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors.

Douglas L Leslie1, Robert A Rosenheck.   

Abstract

Very little is known about patient, provider, and facility characteristics that may affect the likelihood that a schizophrenia patient who receives an antipsychotic medication is dosed according to treatment recommendations. In this study, prescription drug records for schizophrenia patients were collected from the Department of Veterans Affairs, and indicators were constructed describing whether the average daily dose was outside of the range recommended by the schizophrenia Patient Outcomes Research Team (PORT). Generalized estimation equations were used to identify patient, facility, and provider characteristics that are associated with adherence to PORT recommendations. We found that the majority (62.1%) of patients were dosed within the PORT-recommended dosing range. Patients who were older, were female, had comorbid psychiatric disorders, or were prescribed conventional antipsychotics were less likely to adhere to PORT recommendations. Provider and facility characteristics were generally not significantly associated with adherence. When patients were dosed outside of the recommendations, patients treated at facilities with more emphasis on mental health and research and education were more likely to be dosed above the recommendations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15631257     DOI: 10.1093/oxfordjournals.schbul.a007112

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  7 in total

1.  The appropriateness of routine medication treatment for schizophrenia.

Authors:  Alexander S Young; Noosha Niv; Amy N Cohen; Christopher Kessler; Kirk McNagny
Journal:  Schizophr Bull       Date:  2008-11-07       Impact factor: 9.306

Review 2.  A tipping point in drug dosing in late-life schizophrenia.

Authors:  Takashi Tsuboi; Takefumi Suzuki; Hiroyuki Uchida
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

3.  Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study.

Authors:  L Malandain; M Leygues; F Thibaut
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-22       Impact factor: 5.270

4.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

Authors:  Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

5.  Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.

Authors:  Marcela Horvitz-Lennon; Thomas G McGuire; Margarita Alegria; Richard G Frank
Journal:  Health Serv Res       Date:  2009-09-24       Impact factor: 3.402

6.  Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Julie M Donohue; Judith R Lave; Bradley D Stein; Sharon-Lise T Normand
Journal:  Health Serv Res       Date:  2014-03-13       Impact factor: 3.402

7.  Randomized controlled trial of a health plan-level mood disorders psychosocial intervention for solo or small practices.

Authors:  Amy M Kilbourne; Kristina M Nord; Julia Kyle; Celeste Van Poppelen; David E Goodrich; Hyungjin Myra Kim; Daniel Eisenberg; Hyong Un; Mark S Bauer
Journal:  BMC Psychol       Date:  2014-11-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.